

Newly added claims 24-32 merely claim subsets of subject matter contained within claim 1, as filed, and are supported by that claim.

Claims 35-37 merely claim subsets of subject matter contained within claim 12, as filed, and are supported by that claim.

Claims 33 and 38 recite that the polypeptide corresponding to SEQ ID NOs: 45 and 46 exhibits lipase activity, as disclosed in the specification, for example, at page 65, lines 15-22.

Claim 34 is supported in the specification, for example at page 98, lines 23 and 24.

For the foregoing reasons, the Applicants respectfully contend that no new matter has been added by these amendments, and early examination of claims 1-7, 12, and 24-38 on the merits is respectfully requested.

Respectfully submitted,

SEAN A. McCARTHY *et al.*

By:


GARY D. COLBY, Ph.D., J.D.
Registration No. 40,961
AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P.
One Commerce Square
2005 Market Street - 22nd Floor
Philadelphia, PA 19103-7086
Telephone: 215-965-1200
Direct Dial: 215-965-1285
Facsimile: 215-965-1210
E-Mail: GColby@akingump.com

GDC:KML

Enclosures: Marked-Up Copy of Claims Amended
 Clean Copy of Claims, as Amended



**Marked-Up Copy of Claims Amended
In The Preliminary Amendment Filed in Response to the
Restriction Requirement Dated 24 April 2001**

RECEIVED
AUG 21 2001

TECH CENTER 1600/290

1. (Amended) An isolated nucleic acid molecule selected from the group consisting of:

a) a nucleic acid molecule having a nucleotide sequence which is at least 40%-90% identical to the nucleotide sequence of SEQ ID NO: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, or 46, 53, 54, 67, 68, 72, 73, or the nucleotide sequence of a cDNA of a clone deposited as ATCC 207219, 207184, 207228, 207185, 207220, or 207221, or a complement thereof;

b) a nucleic acid molecule comprising at least 15-100 nucleotide residues and having a nucleotide sequence identical to at least 15-100 consecutive nucleotide residues of SEQ ID NO: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, or 46, 53, 54, 67, 68, 72, 73, or the nucleotide sequence of a cDNA of a clone deposited as ATCC 207219, 207184, 207228, 207185, 207220, or 207221, or a complement thereof;

c) a nucleic acid molecule comprising at least 15 nucleotide residues and having a nucleotide sequence identical to at least 15 consecutive nucleotide residues of SEQ ID NO: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, 46, 53, 54, 67, 68, 72, 73, or the nucleotide sequence of a cDNA of a clone deposited as ATCC 207219, 207184, 207228, 207185, 207220, or 207221, or a complement thereof;

d) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, 74, or the amino acid sequence encoded by a cDNA of a clone deposited as ATCC 207219, 207184, 207228, 207185, 207220, or 207221, or a complement thereof encoded by SEQ ID NO: 45 or 46;

ed) a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, 74, or the amino acid sequence encoded by a cDNA of a clone deposited as ATCC 207219, 207184,

- a) a polypeptide comprising the amino acid sequence of SEQ ID NO: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, 74, or the amino acid sequence encoded by a cDNA of a clone deposited as ATCC 207219, 207184, 207228, 207185, 207220, or 207221, or a complement thereof SEQ ID NO: 45 or 46;
- b) a polypeptide comprising a fragment of the amino acid sequence of SEQ ID NO: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, 74, or the amino acid sequence encoded by a cDNA of a clone deposited as ATCC 207219, 207184, 207228, 207185, 207220, or 207221, or a complement thereof, wherein the fragment comprises at least 8 contiguous amino acids of SEQ ID NO: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, 74, or the amino acid sequence encoded by a cDNA of a clone deposited as ATCC 207219, 207184, 207228, 207185, 207220, or 207221, or a complement thereof SEQ ID NO: 45 or 46; and
- c) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, 74, or the amino acid sequence encoded by a cDNA of a clone deposited as ATCC 207219, 207184, 207228, 207185, 207220, or 207221, or a complement thereof SEQ ID NO: 45 or 46, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule consisting of the nucleotide sequence of SEQ ID NO: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, or 46, 53, 54, 67, 68, 72, 73, or the nucleotide sequence of a cDNA of a clone deposited as ATCC 207219, 207184, 207228, 207185, 207220, or 207221, or a complement thereof under stringent conditions;

the method comprising culturing the host cell of claim 5 under conditions in which the nucleic acid molecule is expressed.

~~207228, 207185, 207220, or 207221, wherein the fragment comprises at least 8-18 consecutive amino acid residues of SEQ ID NO: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, 71, or the amino acid sequence encoded by SEQ ID NO: 45 or 46 a cDNA of a clone deposited as ATCC 207219, 207184, 207228, 207185, 207220, or 207221; and~~

~~ef) a nucleic acid molecule which encodes a naturally occurring allele variant of a polypeptide comprising the amino acid sequence of SEQ ID NO: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, 71 the amino acid sequence encoded by SEQ ID NO: 45 or 46, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule consisting of the nucleotide sequence of SEQ ID NO: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, or 46, 53, 54, 67, 68, 72, 73, or the nucleotide sequence of a cDNA of a clone deposited as ATCC 207219, 207184, 207228, 207185, 207220, or 207221, or a complement thereof under stringent conditions.~~

2. (Amended) The isolated nucleic acid molecule of claim 1, which is selected from the group consisting of:

a) a nucleic acid having the nucleotide sequence of SEQ ID NO: ~~1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, or 46, 53, 54, 67, 68, 72, 73, or the nucleotide sequence of a cDNA of a clone deposited as ATCC 207219, 207184, 207228, 207185, 207220, or 207221, or a complement thereof; and~~

b) a nucleic acid molecule which encodes a polypeptide having the amino acid sequence of ~~SEQ ID NO: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, 71, or the amino acid sequence encoded by a cDNA of a clone deposited as ATCC 207219, 207184, 207228, 207185, 207220, or 207221, or a complement thereof SEQ ID NO: 45 or 46.~~

12. (Amended) A method for producing a polypeptide selected from the group consisting of: